Neuren Pharmaceuticals Limited (NURPF)
USD 8.0
(14.29%)
USD 8.0
(14.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 157.08 Million AUD | 85270.11% |
| 2022 | 184 Thousand AUD | 102.36% |
| 2021 | -7.79 Million AUD | 15.22% |
| 2020 | -9.19 Million AUD | 15.01% |
| 2019 | -10.81 Million AUD | -451.97% |
| 2018 | 3.07 Million AUD | 269.97% |
| 2017 | -1.8 Million AUD | 84.95% |
| 2016 | -12.01 Million AUD | 10.32% |
| 2015 | -13.39 Million AUD | -61.47% |
| 2014 | -8.29 Million AUD | 26.57% |
| 2013 | -11.29 Million AUD | -121.82% |
| 2012 | -5.09 Million AUD | -9.53% |
| 2011 | -4.65 Million AUD | 4.96% |
| 2010 | -4.89 Million AUD | -5014.85% |
| 2009 | 99.56 Thousand AUD | 100.65% |
| 2008 | -15.41 Million AUD | -26.88% |
| 2007 | -12.15 Million AUD | -20.13% |
| 2006 | -10.11 Million AUD | -21.75% |
| 2005 | -8.3 Million AUD | -45.91% |
| 2004 | -5.69 Million AUD | -0.83% |
| 2003 | -5.64 Million AUD | -3.46% |
| 2002 | -5.45 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 4 Million AUD | -96.33% |
| 2024 Q2 | 4 Million AUD | 0.0% |
| 2023 Q1 | 23.9 Million AUD | 230.24% |
| 2023 Q4 | 109.27 Million AUD | 100.0% |
| 2023 FY | 157.08 Million AUD | 85270.11% |
| 2023 Q3 | 54.63 Million AUD | 14.29% |
| 2023 Q2 | 47.8 Million AUD | 100.0% |
| 2022 Q2 | -7.05 Million AUD | -100.0% |
| 2022 Q1 | -3.52 Million AUD | -2174.71% |
| 2022 Q3 | 3.61 Million AUD | 151.3% |
| 2022 Q4 | 7.23 Million AUD | 100.0% |
| 2022 FY | 184 Thousand AUD | 102.36% |
| 2021 Q3 | 85 Thousand AUD | 101.07% |
| 2021 FY | -7.79 Million AUD | 15.22% |
| 2021 Q4 | 170 Thousand AUD | 100.0% |
| 2021 Q1 | -3.98 Million AUD | 10.15% |
| 2021 Q2 | -7.96 Million AUD | -100.0% |
| 2020 Q2 | -4.76 Million AUD | -100.0% |
| 2020 Q4 | -4.43 Million AUD | -100.0% |
| 2020 Q3 | -2.21 Million AUD | 53.46% |
| 2020 Q1 | -2.38 Million AUD | 18.78% |
| 2020 FY | -9.19 Million AUD | 15.01% |
| 2019 FY | -10.81 Million AUD | -451.97% |
| 2019 Q2 | -7.88 Million AUD | -100.0% |
| 2019 Q3 | -1.46 Million AUD | 81.41% |
| 2019 Q1 | -3.94 Million AUD | -209.99% |
| 2019 Q4 | -2.93 Million AUD | -100.0% |
| 2018 Q3 | 3.58 Million AUD | 275.02% |
| 2018 Q1 | -2.04 Million AUD | -159.88% |
| 2018 Q4 | 3.58 Million AUD | 0.0% |
| 2018 FY | 3.07 Million AUD | 269.97% |
| 2018 Q2 | -2.04 Million AUD | 0.0% |
| 2017 Q1 | -1.77 Million AUD | 23.38% |
| 2017 FY | -1.8 Million AUD | 84.95% |
| 2017 Q3 | 3.42 Million AUD | 292.57% |
| 2017 Q2 | -1.77 Million AUD | 0.0% |
| 2017 Q4 | 3.42 Million AUD | 0.0% |
| 2016 Q2 | -3.68 Million AUD | 0.0% |
| 2016 FY | -12.01 Million AUD | 10.32% |
| 2016 Q1 | -3.68 Million AUD | 8.34% |
| 2016 Q4 | -2.31 Million AUD | 0.0% |
| 2016 Q3 | -2.31 Million AUD | 37.16% |
| 2015 FY | -13.39 Million AUD | -61.47% |
| 2015 Q4 | -4.02 Million AUD | 0.0% |
| 2015 Q1 | -2.67 Million AUD | -46.88% |
| 2015 Q2 | -2.67 Million AUD | 0.0% |
| 2015 Q3 | -4.02 Million AUD | -50.5% |
| 2014 Q3 | -1.82 Million AUD | 21.8% |
| 2014 Q1 | -2.32 Million AUD | 36.86% |
| 2014 Q4 | -1.82 Million AUD | 0.0% |
| 2014 FY | -8.29 Million AUD | 26.57% |
| 2014 Q2 | -2.32 Million AUD | 0.0% |
| 2013 Q3 | -3.68 Million AUD | -140.82% |
| 2013 FY | -11.29 Million AUD | -121.82% |
| 2013 Q2 | -1.53 Million AUD | 0.0% |
| 2013 Q1 | -1.53 Million AUD | 0.0% |
| 2013 Q4 | -3.68 Million AUD | 0.0% |
| 2012 FY | -5.09 Million AUD | -9.53% |
| 2011 FY | -4.65 Million AUD | 4.96% |
| 2010 FY | -4.89 Million AUD | -5014.85% |
| 2009 FY | 99.56 Thousand AUD | 100.65% |
| 2008 FY | -15.41 Million AUD | -26.88% |
| 2007 FY | -12.15 Million AUD | -20.13% |
| 2006 FY | -10.11 Million AUD | -21.75% |
| 2005 FY | -8.3 Million AUD | -45.91% |
| 2004 FY | -5.69 Million AUD | -0.83% |
| 2003 FY | -5.64 Million AUD | -3.46% |
| 2002 FY | -5.45 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | 3770.115% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 309.545% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 57554.225% |
| SQZ Biotechnologies Company | -79.46 Million USD | 297.676% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 5530.83% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -196.497% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -141.17% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 8728.321% |
| Marizyme, Inc. | -65.34 Million USD | 340.38% |
| Genus plc | 7.9 Million USD | -1888.367% |
| Pharming Group N.V. | -10.54 Million USD | 1589.202% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 7339.376% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 4333.722% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 1876.131% |
| ContraFect Corporation | -65.15 Million USD | 341.096% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 9193.204% |
| IMV Inc. | -36.48 Million USD | 530.528% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 2048.973% |
| ONE Bio Corp. | 8.67 Million USD | -1710.396% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 403.879% |
| Mesoblast Limited | -87.95 Million USD | 278.59% |
| MultiCell Technologies, Inc. | -380.07 USD | 41329591.936% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 4307.902% |
| Genscript Biotech Corporation | -95.47 Million USD | 264.522% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 24938.593% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 6697.63% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 2488.661% |
| Biomind Labs Inc. | -1.21 Million USD | 13035.728% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 5164.241% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 2087.589% |
| Skye Bioscience, Inc. | -37.64 Million USD | 517.272% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 8158.539% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 1542.203% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 1048984.882% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 3314.879% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 2349.53% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 1089.708% |
| Accustem Sciences Inc. | -3.74 Million USD | 4292.831% |
| EV Biologics, Inc. | -1.26 Million USD | 12496.558% |
| Q BioMed Inc. | -2.05 Million USD | 7754.673% |
| GB Sciences, Inc. | -1.36 Million USD | 11635.849% |
| Alpha Cognition Inc. | -13.77 Million USD | 1240.535% |
| CSL Limited | 2.64 Billion USD | 94.054% |
| Agentix Corp. | -1.37 Million USD | 11530.632% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 363.005% |
| Enzolytics Inc. | -2.17 Million USD | 7316.037% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -3.61 Million USD | 4451.274% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 5052.993% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 2800.261% |
| argenx SE | -295.05 Million USD | 153.238% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 350.932% |
| HST Global, Inc. | -146.21 Thousand USD | 107535.196% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -160186.735% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 9051.652% |
| Halberd Corporation | -79.67 Thousand USD | 197249.706% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -2168.451% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 5290.813% |
| Zenith Capital Corp. | -10.59 Million USD | 1582.456% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 4053.72% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 3888.795% |
| AVAX Technologies, Inc. | -6.41 Million USD | 2549.168% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 259993.141% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 7934.015% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 675949.755% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 3393.664% |
| Helix BioMedix, Inc. | -1.05 Million USD | 14974.292% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 4213.145% |
| Kadimastem Ltd | -3.3 Million USD | 4849.383% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 1951.719% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 35689.495% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 11862.57% |
| LadRx Corporation | 400.44 Thousand USD | -39126.806% |
| Cell Source, Inc. | -5.32 Million USD | 3051.978% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 37907.206% |
| Regen BioPharma, Inc. | 1.02 Million USD | -15247.315% |
| Regen BioPharma, Inc. | 1.02 Million USD | -15247.315% |
| Affymax, Inc. | -14.42 Million USD | 1189.025% |
| Mobile Lads Corp. | -2.26 Million USD | 7040.377% |
| Itoco Inc. | -1.86 Million USD | 8504.57% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 3635.842% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 9511.684% |
| International Stem Cell Corporation | -131 Thousand USD | 120009.16% |
| CytoDyn Inc. | -49.84 Million USD | 415.164% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 198853.685% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 68956.821% |
| Qrons Inc. | -789.34 Thousand USD | 20000.12% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 16783.607% |
| SYBLEU INC | -180.3 Thousand USD | 87220.086% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 7624.182% |
| Rebus Holdings, Inc. | -1.02 Million USD | 15500.098% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 9840.026% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 289532.857% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 6308.129% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 426.762% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 7530.511% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 20215.715% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 5058.365% |
| Neutra Corp. | -233.46 Thousand USD | 67382.462% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 874.141% |
| PureTech Health plc | -65.69 Million USD | 339.099% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 838.63% |
| IXICO plc | -1.17 Million USD | 13434.55% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 1682.361% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 374.963% |
| CSL Limited | 2.64 Billion USD | 94.054% |
| Cellectis S.A. | -103.17 Million USD | 252.249% |